FindTrial
Sign In

Study of Oral Zinc Supplementation in Preterm Neonates

A Randomised Placebo Controlled Double Blinded Study Of Oral Zinc supplementation in Preterm Neonates with Indirect Hyperbilirubinemia - Interventional

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/100084
Enrollment
60
Registered
2026-01-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P590- Neonatal jaundice associated withpreterm delivery

Interventions

Intervention1: Nil: Nil Intervention2: ORAL ZINC Sulphate: Oral Zinc Sulphate 0.5ML Twice Daily FOR Three Days In Preterm With Indirect Hyperbilirubinemia Study period -18 months Control Intervention

Sponsors

Rakshitha V
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Preterm Neonates With Indirect Hyperbilirubinemia

Exclusion criteria

Exclusion criteria: RH INCOMPATIBILITY TERM NEONATES SEPSIS

Design outcomes

Primary

MeasureTime frame
Levels of serum bilirubin at Baseline,24hours and 48 hoursTimepoint: Levels of serum bilirubin at Baseline, 24 hours and 48 hours—

Secondary

MeasureTime frame
NILTimepoint:—

Countries

India

Contacts

Public ContactDr Sunil B

KIMS Hospital and research center

docsunilb@gmail.com9900485879

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026